Abstract
Estrogen plays vital roles in human health and diseases. Estrogen mediates its actions almost entirely by binding to estrogen receptors (ER), alpha and beta which further function as transcription factors. Selective estrogen receptor modulators (SERMs) are synthetic molecules which bind to ER and can modulate its transcriptional capabilities in different ways in diverse estrogen target tissues. Tamoxifen, the prototypical SERM, is extensively used for targeted therapy of ER positive breast cancers and is also approved as the first chemo-preventive agent for lowering breast cancer incidence in high risk women. The therapeutic and preventive efficacy of tamoxifen was initially proven by series of experiments in the laboratory which laid the foundation of its clinical use. Unfortunately, use of tamoxifen is associated with de-novo and acquired resistance and some undesirable side effects. The molecular study of the resistance provides an opportunity to precisely understand the mechanism of SERM action which may further help in designing new and improved SERMs. Recent clinical studies reveal that another SERM, raloxifene, which is primarily used to treat post-menopausal osteoporosis, is as efficient as tamoxifen in preventing breast cancers with fewer side effects. Overall, these findings open a new horizon for SERMs as a class of drug which not only can be used for therapeutic and preventive purposes of breast cancers but also for various other diseases and disorders. Major efforts are therefore directed to make new SERMs with a better therapeutic profile and fewer side effects.
Keywords: Breast cancer, osteoporosis, estrogen receptor, tamoxifen, raloxifene, SERMs, endocrine therapy, drug resistance
Anti-Cancer Agents in Medicinal Chemistry
Title: Potential of Selective Estrogen Receptor Modulators as Treatments and Preventives of Breast Cancer
Volume: 9 Issue: 5
Author(s): Jing Peng, Surojeet Sengupta and V. Craig Jordan
Affiliation:
Keywords: Breast cancer, osteoporosis, estrogen receptor, tamoxifen, raloxifene, SERMs, endocrine therapy, drug resistance
Abstract: Estrogen plays vital roles in human health and diseases. Estrogen mediates its actions almost entirely by binding to estrogen receptors (ER), alpha and beta which further function as transcription factors. Selective estrogen receptor modulators (SERMs) are synthetic molecules which bind to ER and can modulate its transcriptional capabilities in different ways in diverse estrogen target tissues. Tamoxifen, the prototypical SERM, is extensively used for targeted therapy of ER positive breast cancers and is also approved as the first chemo-preventive agent for lowering breast cancer incidence in high risk women. The therapeutic and preventive efficacy of tamoxifen was initially proven by series of experiments in the laboratory which laid the foundation of its clinical use. Unfortunately, use of tamoxifen is associated with de-novo and acquired resistance and some undesirable side effects. The molecular study of the resistance provides an opportunity to precisely understand the mechanism of SERM action which may further help in designing new and improved SERMs. Recent clinical studies reveal that another SERM, raloxifene, which is primarily used to treat post-menopausal osteoporosis, is as efficient as tamoxifen in preventing breast cancers with fewer side effects. Overall, these findings open a new horizon for SERMs as a class of drug which not only can be used for therapeutic and preventive purposes of breast cancers but also for various other diseases and disorders. Major efforts are therefore directed to make new SERMs with a better therapeutic profile and fewer side effects.
Export Options
About this article
Cite this article as:
Peng Jing, Sengupta Surojeet and Jordan Craig V., Potential of Selective Estrogen Receptor Modulators as Treatments and Preventives of Breast Cancer, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (5) . https://dx.doi.org/10.2174/187152009788451833
DOI https://dx.doi.org/10.2174/187152009788451833 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Purine-Scaffold Hsp90 Inhibitors
Current Topics in Medicinal Chemistry Application of Natural Dye Obtained from Sweet Indrajao on Fabrics
Current Biochemical Engineering (Discontinued) Basic and Clinical Research Against Advanced Glycation End Products (AGEs): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications
Recent Advances in Cardiovascular Drug Discovery (Discontinued) PET in Anti-Cancer Drug Development and Therapy
Recent Patents on Anti-Cancer Drug Discovery Functional Foods: Salient Features and Clinical Applications
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Targeting Tumour Metastasis: The Emerging Role of Nanotechnology
Current Medicinal Chemistry Measles Virus as An Oncolytic Vector Platform
Current Gene Therapy Src Family Nonreceptor Tyrosine Kinases as Molecular Targets for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Pharmaco-Therapeutic Challenges in Cancer Biology with Focus on the Immune- System Related Risk Factors
Current Pharmaceutical Design Nitric Oxide and Dietary Factors: Part IV Traditional Japanese Food (Soy Products, Fish and Tea)
Vascular Disease Prevention (Discontinued) HSV-1-Derived Recombinant and Amplicon Vectors for Gene Transfer and Gene Therapy
Current Gene Therapy Targeting IL-17 and IL-23 in Immune Mediated Renal Disease
Current Medicinal Chemistry Ultrasound Assisted Synthesis of 3-(het)aryl Isocoumarin Derivatives and their in vitro Pharmacological Evaluation
Mini-Reviews in Medicinal Chemistry Nanoradiopharmaceuticals for Nanomedicine: Building the Future
Recent Patents on Nanomedicine The Changing Face of HIV/AIDS in Treated Patients
Current HIV Research Preclinical Profile of Bacopasides From Bacopa monnieri (BM) As An Emerging Class of Therapeutics for Management of Chronic Pains
Current Medicinal Chemistry Importance of Kier-Hall Topological Indices in the QSAR of Anticancer Drug Design
Current Computer-Aided Drug Design Cancer Kinases and its Novel Inhibitors: Past, Present and Future Challenges
Current Drug Targets Contribution of Magnetic Resonance Imaging in Determining Lumpectomy Cavity in Breast Radiotherapy
Current Medical Imaging Biologically Active Selenophenes and Benzo[b]selenophenes
Current Organic Synthesis